Search
News
UL Solutions Q2 2026 earnings: Organic growth and adjusted margins improve
UL Solutions’ Q2 2026 revenue rose 5.2% to $816 million, with organic revenue growth of 6.6%. Diluted EPS increased to $1.21 from $0.45, but a gain on the sale of its Employee Health and Safety software business was a major driver of GAAP profit. Adjusted EBITDA grew 11.2% to $219 million and adjusted EBITDA margin expanded 140 basis points to 26.8%, supported by higher revenue, productivity, cost improvements and operating leverage. The 2026 outlook targets mid-single-digit constant-currency organic growth and an adjusted EBITDA margin of approximately 27.0%.
TradingKey
Wed, Aug 5
Knife River Q2 2026 earnings: Revenue rises as margins narrow
Knife River’s Q2 2026 revenue rose 13% to $938.6 million, but net income fell 13% to $43.9 million and diluted EPS declined to $0.77. Adjusted EBITDA was nearly flat at $139.7 million, while its margin contracted to 14.9% from 16.9%. Contracting services revenue grew 20%, yet lower-margin work, project timing, energy costs and fewer asset-sale gains weighed on profitability. The company raised full-year revenue and aggregate-volume guidance, with revenue now expected at $3.4 billion to $3.6 billion, and ended June with a $1.216 billion contracting backlog.
TradingKey
Wed, Aug 5
Broadridge Fiscal Q4 2026 Earnings: Recurring Revenue Grew 8%
Broadridge Financial Solutions’ fiscal Q4 2026 revenue increased 7% to $2.22 billion, recurring revenue grew 8% to $1.54 billion, and diluted EPS rose 9% to $3.44. Investor Communication Solutions led recurring growth, while Global Technology and Operations expanded its pre-tax margin to 13.8% from 7.3%. For fiscal 2027, Broadridge expects 6%-8% constant-currency recurring revenue growth, 8%-12% adjusted EPS growth, and free cash flow conversion of at least 100%, even as GAAP EPS growth is guided between negative 4% and flat.
TradingKey
Wed, Aug 5
OPENLANE Q2 2026 earnings: Marketplace volumes drive 15% revenue growth
OPENLANE’s Q2 2026 revenue rose 15% to $554.6 million as auction and related fees increased 21% and marketplace GMV climbed 41% to about $10.5 billion. Net income advanced 33% to $44.3 million, while diluted EPS increased to $0.32 from $0.15 and adjusted EBITDA reached $103.2 million. Quarterly operating cash flow fell to $52.8 million despite higher earnings. The company raised its 2026 adjusted EBITDA guidance to $385 million-$400 million, supported by commercial off-lease activity and U.S. dealer volume growth.
TradingKey
Wed, Aug 5
Urban One Q2 2026 earnings: Revenue decline weighs on adjusted EBITDA
Urban One’s fiscal Q2 2026 net revenue fell 6.4% to $85.8 million, while basic and diluted EPS improved to -$1.58 from -$17.41. Adjusted EBITDA declined to $11.7 million from $14.0 million as revenue fell across Radio, Reach Media, Digital and Cable Television. The much smaller GAAP loss mainly reflected impairment charges dropping to $14.2 million from $130.1 million. Management revised full-year adjusted EBITDA guidance to the mid-$50 million range while continuing to reduce long-term debt and increasing short-term borrowing.TradingKey
Wed, Aug 5
McDonald’s Q2 2026 Earnings: Revenue Grows as Comparable Sales Slow
McDonald’s Q2 2026 revenue rose 4% to $7.10 billion, while diluted EPS increased 6% to $3.32 and net income advanced 5% to $2.36 billion. Global comparable sales remained positive across all three segments but slowed to 1.3% from 3.8% a year earlier, with U.S. comparable sales up 0.8% as higher average checks were partly offset by lower guest counts. Higher franchised margins and other operating income supported profit growth, while higher selling, general and administrative expenses remained a pressure point.
TradingKey
Wed, Aug 5
Reservoir Media Q1 FY2027 Earnings: Recorded Music Drives 12% Revenue Growth
Reservoir Media’s fiscal Q1 2027 revenue rose 12% to $41.5 million, with organic growth of 6%, as Recorded Music revenue climbed 35%. Adjusted EBITDA increased 13% to $15.7 million, but GAAP operating income slipped 1% to $5.4 million as administration and depreciation and amortization costs increased. The company posted a $0.5 million consolidated net loss, improved operating cash use by $7.4 million, and reaffirmed fiscal 2027 revenue guidance of $186 million to $191 million while net debt rose during the quarter.
TradingKey
Wed, Aug 5
Wayfair Q2 2026 Earnings: U.S. Growth Drives a 7.5% Revenue Increase
Wayfair’s Q2 2026 revenue rose 7.5% to $3.519 billion, led by 8.7% U.S. growth, while international revenue slipped 1.3%. GAAP diluted EPS was a $0.01 loss versus $0.11 of earnings a year earlier, as a $59 million debt-extinguishment loss and higher interest expense offset stronger operating income. Adjusted EBITDA increased to $242 million, and free cash flow reached $301 million, the company’s strongest since 2020. Orders grew 6.0%, active customers increased 3.3%, and gross margin remained broadly stable at 30.0%.
TradingKey
Wed, Aug 5
BioNTech Q2 2026 Earnings: Lower COVID Vaccine Demand Deepens Losses
BioNTech’s Q2 2026 revenue fell about 59.5% year over year to €105.6 million as demand for its COVID-19 vaccines declined, while IFRS diluted EPS worsened to a €3.24 loss from a €1.60 loss. The company cut full-year revenue guidance to €1.6 billion–€1.9 billion, citing weaker global vaccine demand, use of existing German inventory and milestone revenue no longer expected in 2026. Oncology development continued to expand, but higher pipeline-related costs and prioritization charges widened the quarterly net loss despite positive operating cash flow.
TradingKey
Wed, Aug 5
BioNTech Q2 2026 Earnings: Lower Vaccine Revenue Deepens Losses
BioNTech’s Q2 2026 revenue fell to €105.6 million from €260.8 million as COVID-19 vaccine demand weakened, while the IFRS net loss widened to €820.8 million and diluted loss per share reached €3.24. Quarterly operating cash flow remained positive at €10.5 million, and cash plus security investments totaled €16.6 billion at June 30. The company cut full-year revenue guidance to €1.6 billion–€1.9 billion, lowered adjusted R&D guidance and continued advancing an oncology pipeline with 14 pivotal trials underway.TradingKey
Wed, Aug 5
Energizer Fiscal Q3 2026 Earnings: Organic Sales Rise as Margins Contract
Energizer’s fiscal Q3 2026 net sales rose 1.2% to $734.1 million, with organic sales up 2.7%. Diluted EPS fell to $0.58 from $2.13, while adjusted EPS was $0.75 and adjusted gross margin declined 560 basis points to 39.2%. Auto Care led revenue growth, but unfavorable mix, promotional investment and a difficult production-credit comparison pressured profit. The company now expects full-year adjusted EPS and adjusted EBITDA at the low ends of their original ranges, while nine-month free cash flow improved to $105.0 million.
TradingKey
Wed, Aug 5
Wheels Up Q2 2026 Earnings: Gross Profit Rises as Net Loss Widens
Wheels Up reported Q2 2026 revenue of $182.0 million, down 4% year over year, while gross profit rose to $9.6 million and gross margin expanded to 5.3% from 1.2%. The net loss widened to $107.2 million, or $2.97 per diluted share, as higher interest and aircraft lease costs and a $12.7 million legacy-fleet impairment outweighed operating gains. Premium fleet utility increased 20%, adjusted EBITDAR loss narrowed 27%, and completion rate reached 99.4%. However, bookings fell 8% and six-month operating cash outflow increased to $191.3 million.
TradingKey
Wed, Aug 5
Timken Q2 2026 earnings: Adjusted margin expands as belts charge weighs on GAAP profit
Timken's Q2 2026 net sales rose 7.5% to $1.26 billion, while diluted EPS fell to $0.41 from $1.12 as belts-related impairment and restructuring charges weighed on GAAP profit. Adjusted EPS increased 28.9% to $1.83, and adjusted EBITDA margin expanded 190 basis points to 19.6%, helped by higher volume, price/mix and an $8.0 million net tariff-refund benefit. Industrial Motion led segment growth, and Timken raised its full-year adjusted EPS outlook to $6.05-$6.35 while lifting its 2026 revenue-growth midpoint to about 5.5%.
TradingKey
Wed, Aug 5
AMETEK Q2 2026 earnings: 15% sales growth supports higher guidance
AMETEK’s Q2 2026 revenue increased 15% year over year to $2.04 billion, while adjusted diluted EPS rose 17% to $2.09 and operating cash flow climbed 35% to $483.7 million. EMG delivered the sharper profit expansion, with adjusted operating income up 32%, while EIG’s core margin improved despite acquisition dilution. The company raised full-year adjusted EPS guidance to $8.20-$8.30 and now expects approximately 10% sales growth, supported by 28% order growth during the quarter and contributions from organic demand and recent acquisitions.
TradingKey
Wed, Aug 5
Aptiv Q2 2026 Earnings: Margins Expand as Cash Flow Weakens
Aptiv’s Q2 2026 revenue rose 2% year over year to $3.274 billion, while diluted EPS from continuing operations increased to $1.40 from $1.21. Adjusted EBITDA reached $613 million and margin expanded 160 basis points to 18.7%, supported by higher volumes and favorable foreign exchange, partly offset by commodity costs. However, operating cash flow fell to $137 million and free cash flow declined to $12 million. The quarter was Aptiv’s first after completing the Electrical Distribution Systems spin-off, and full-year guidance reflects the continuing New Aptiv business.
TradingKey
Wed, Aug 5
Versigent Q2 2026 earnings: EBITDA margin expands on higher volumes
Versigent's (NYSE: VGNT) Q2 2026 net sales rose 10.8% to $2.44 billion, while diluted EPS increased to $1.64 from $1.51. Adjusted EBITDA climbed 24.8% to $272 million and margin expanded 120 basis points to 11.1%, supported by higher volumes and operating execution, although interest and tax expense held net margin to 4.8%. The company raised and tightened full-year sales guidance to $9.4-$9.6 billion but maintained its adjusted EBITDA and free cash flow ranges, as the sales revision reflected commodity pass-through and foreign exchange effects.
TradingKey
Wed, Aug 5
Pfizer Q2 2026 Earnings: Non-COVID Growth Raises Revenue Outlook
Pfizer’s Q2 2026 revenue rose 3% to $15.03 billion, with non-COVID revenue up 5% operationally, while adjusted diluted EPS was $0.77 versus $0.78 a year ago. A $4.3 billion non-cash intangible-asset impairment drove a reported loss of $0.04 per share despite nearly flat adjusted income. Growth in Eliquis, Padcev, Vyndaqel and Lorbrena offset steep declines in Paxlovid and Comirnaty. Pfizer raised the midpoint of 2026 revenue guidance to $61.5 billion and maintained adjusted EPS guidance of $2.80 to $3.00.
TradingKey
Wed, Aug 5
Brightstar Lottery Q2 2026 Earnings: EBITDA Rises Despite Revenue Decline
Brightstar Lottery’s Q2 2026 revenue fell 7% year over year to $584 million, as higher Italy Lotto service revenue amortization, the U.K. contract transition, and lower product sales offset 1.5% global same-store sales growth. Adjusted EBITDA increased 4% to $286 million and margin rose to 48.9%, while diluted EPS from continuing operations improved to $0.18 from a $0.47 loss. Quarterly operating cash flow was negative $1.34 billion after the $1.67 billion final Italy Lotto license payment. Brightstar reaffirmed its full-year 2026 outlook.
TradingKey
Wed, Aug 5
Havertys Q2 2026 Earnings: Sales Rise 7.7% as EPS Doubles
Havertys Q2 2026 revenue rose 7.7% to $194.9 million, comparable-store sales increased 8.0%, and diluted EPS doubled to $0.32. GAAP gross margin reached 61.4%, but excluding roughly $1.5 million of IEEPA tariff refunds, it was 60.7% versus 60.8% a year earlier. Six-month operating cash flow improved to $21.4 million, while the company maintained its 60.5%-61.0% full-year gross-margin outlook and raised variable SG&A expectations because of higher selling expenses. Store expansion also lifted planned 2026 capital expenditures to approximately $34 million.TradingKey
Wed, Aug 5
SOPHiA GENETICS Q2 2026 earnings: Revenue rises 27% as adjusted EBITDA loss narrows
SOPHiA GENETICS reported Q2 2026 revenue of $23.3 million, up 27% year over year, while basic and diluted loss per share narrowed to $0.30 from $0.33. IFRS net loss was roughly flat at $22.4 million, but adjusted EBITDA loss improved 27% to $8.8 million. Reported gross margin declined to 64.6% from 67.0%. U.S. and Liquid Biopsy growth supported revenue, the full-year revenue outlook rose to $94 million-$96 million, and cash reached $107.7 million following equity financing.
TradingKey
Wed, Aug 5
Featured Tools
Top News
New CEO Ternus Launches iPhone 18 Pro on September 9 — Can Apple Reverse Q3 China Miss Before Jackson Hole?
Oracle Stock Forecast: $630 Billion AI Order Backlog Awaits Revaluation, Can the Stock Continue to Recover?
Micron vs. SK Hynix: As HBM Demand Continues to Surge, Which Memory Stock Deserves More Attention?
Cerebras Cloud Revenue Nearly Quadrupled — But Why Did the Stock Crash 17% on "Confusing" GAAP Results?
Western Digital Shares Plunge 50%: Is It the Best Time to Buy?
